Physician profile
Seema Mohan
NPI 1588604177
$2,552.07
in general payments reported to CMS, 2019-2025
32 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $74.48 · 2021: $252 · 2022: $417 · 2023: $620 · 2024: $614 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.49 | 2019-2025 | |
| Amgen INC. | $310.23 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $196.59 | 2019-2025 | |
| Boston Scientific Corporation | $187.62 | 2021-2023 | Watchman Access System |
| Shockwave Medical, INC | $165.22 | 2022 | |
| Lilly USA, LLC | $152.36 | 2022-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $145.01 | 2024 | |
| Sanofi Pasteur INC. | $119.01 | 2019-2025 | |
| Exact Sciences Corporation | $99.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $96.19 | 2023 | Tepezza |
| Astellas Pharma US INC | $91.84 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $73.23 | 2023-2024 | Shingrix, Arexvy |
| Atricure, INC. | $61.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $52.89 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.96 | 2021-2025 | Andexxa, Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.64 | 2023-2024 | Wegovy |
| Ibsa Pharma INC. | $38.89 | 2022-2024 | Tirosint, Licart |
| Acella Pharmaceuticals, LLC | $36.86 | 2024-2025 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $30.66 | 2024 | Quviviq |
| Allergan, INC. | $30.14 | 2019-2020 | |
| Medtronic USA, INC. | $26.17 | 2019 | |
| Philips North America LLC | $24.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.43 | 2023 | Trintellix |
| Therapeuticsmd, INC. | $21.70 | 2019 | |
| Lucid Diagnostics INC. | $20.81 | 2023 | |
| Intra-Sana Laboratories | $19.33 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Avanir Pharmaceuticals, INC. | $19.00 | 2019 | |
| Neurelis, INC. | $18.94 | 2022 | |
| Abbott Laboratories | $17.61 | 2019 | |
| Esperion Therapeutics, INC. | $17.34 | 2025 | Nexletol |
| Vistapharm, INC. | $14.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.